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Background: There is an increased interest in evaluating the impact of core symptoms of schizophrenia, both
positive and negative, on functioning and burden of disease.
Objective: To examine the extent towhich prominent positive andprominent negative symptoms impact functional
health, well-being, health-related quality of life (HRQoL), and family burden.
Methods: Data on symptomatology, HRQoL, and resource use from the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) were analyzed (n = 1447). Patients were divided into four groups based on the Positive and
Negative Syndrome Scale (PANSS) using published criteria as having (a) neither prominent positive nor prominent
negative symptoms (n = 575; 39.7%); (b) only prominent negative symptoms (n =274; 18.9%); (c) only promi-
nent positive symptoms (n = 295; 20.4%); or (d) both prominent positive and negative symptoms (n = 303;
20.9%). Differences were examined for overall signiﬁcance between the groups and for a linear trend.
Results: There was a signiﬁcant linear decline in the outcome measures with each subsequent symptom group,
with the combination of prominent positive and negative symptoms incrementing the decline further on
quality-adjusted life-years derived from the PANSS, Short-Form-12, Index of Functioning, HRQoL measures,
and number of workdays missed by caregiver during the month prior to CATIE (all p b 0.001).
Conclusions: Both prominent positive and prominent negative symptoms of schizophrenia are independently
associated with signiﬁcant decline in functionality, HRQoL, and caregiver lost workdays. An increased burden is
observed in patients with highest symptomatology. Further research is needed to determine predictors of poor
outcomes and burden of schizophrenia.© 2013 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-SA license. 1. Introduction
There is an increased interest in the impact of core symptoms of
schizophrenia, both positive and negative, on health-related quality
of life (HRQoL), patient functioning, and burden of disease on the
affected individual and his or her family. Although the introduction
of second-generation antipsychotics was expected to lead to a break-
through in the treatment of negative symptoms, evidence suggests
that these treatments primarily treat the positive symptoms of
schizophrenia and have only a modest impact on negative symptoms.
The severity of negative symptoms is a predictor of poor patientabinowitz),
arski-kirola@roche.com
.V.Open access under CC BY-NC-SA licfunctioning. Negative symptoms affect the patient's ability to live in-
dependently, to perform activities of daily living, to be socially active
and maintain personal relationships, and to work and study (Alonso
et al., 2009; Harvey et al., 2012; Rabinowitz et al., 2012). Under-
standing the relationship between domains of psychopathology and
clinical outcomes is important because interventions that focus on
psychotic symptoms often fail to improve functioning and HRQoL.
Long-term treatment goals for patients with schizophrenia include
improving the management of negative symptoms and subobtimally
controlled positive symptoms and enabling better functioning (Kane,
2006; Kirkpatrick et al., 2006; Bobes et al., 2010). We examined the
extent to which prominent positive and prominent negative symptoms
are associated with functional health, patient well-being, HRQoL, and
family burden.
2. Methods
Data on baseline symptomatology, HRQoL, and resource use from
the National Institute of Mental Health Clinical Antipsychotic Trialsense. 
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CATIE was a randomized controlled trial that compared a ﬁrst-
generation antipsychotic, perphenazine, with four second generation
antipsychotics (olanzapine, quetiapine, risperidone and ziprasidone)
for up to 18 months in a double-blind study. Patients with schizo-
phrenia were recruited at 57 U.S. sites. The primary aim was to delin-
eate differences in the overall effectiveness of these ﬁve treatments.
Broad inclusion and minimal exclusion criteria were used to allow
enrollment of patients with coexisting conditions and those who
were taking other medications. The study was conducted in a variety
of clinical settings in which people with schizophrenia are treated
with 76% of patients entering study as outpatients (Lieberman et al.,
2005).
Measures analyzed were the Positive and Negative Syndrome
Scale (PANSS); Short Form Health Survey (SF-12) measure of func-
tional health and well-being; Index of Functioning (Rabinowitz et
al., 2012); and caregiver days lost from work in the past month in
or out of the home (Family/Caregiver Baseline Interview).
The Index of Functioning has been previously described (Rabinowitz
et al., 2012). It included items from the Heinrich and Lehman scales that
conceptually did notmeasure negative factor symptoms. It included from
the Heinrich's Carpenter the scales Instrumental role (occupational/
educational), Common place objects and activities, and from the
Lehman Quality of Life Scales two items that measure Leisure activities
(Shopping, Go to restaurant/coffee shop, Prepare meal, Hobby) and
Instrumental activities of daily living (hygiene, housecleaning, chores).
Two Heinrich's subscales, measuring interpersonal relations and intra-
psychic foundations were intentionally not included as they overlap
with the negative symptom factor. Of the nine items from the Lehman's
Quality of Life Scale included in CATIE, seven items overlapping with
negative symptoms, or that had already been covered by the Heinrech's
scale were not included (e.g. school andwork functioning). Functioning
itemswere converted to standardized scores (z-scores) and summed to
create a total score.
2.1. Data analysis
Patientswere categorized into four groups based on the PANSS, using
published criteria (Kinon et al., 2006): (a) neither prominent positiveTable 1
Association of PANSS Symptom Prominence: PANSS, SF-12 Mental Health Score, SF-6D Utilit
95% Conﬁdence Interval.
PANSS Symptom
Prominence Group
PANSS
Total
Positive Negative SF-12
Mental
Health
SF-6D Util
Effect Size
Neither Gr
None 39.7%
(n = 575)
62
(61; 63)
16
(14; 16)
16
(15; 16)
43.3
(42.3; 44.2)
0.725
(0.714; 0.7
Prominent negative
18.9% (n = 274)†
80
(78; 81)
16
(15; 16)
26
(25; 26)
40.5
(39.6; 42.4)
0.696
(0.680; 0.7
ES vs. Neit
group = 0
Prominent positive 20.4%
(n = 295)‡
78
(77; 79)
23
(22; 23)
17
(16; 17)
39.4
(38.0; 40.8)
0.685
(0.669; 0.6
ES vs. Neit
group = 0
Both prominent negative
and prominent positive
20.9% (n = 303)
95
(94; 97)
24
(23; 24)
26
(26; 27)
37.9
(36.5; 39.2)
0.683
(0.668; 0.6
ES vs. Neit
group = 0
Overall p value b0.001 b0.001 b0.001 b0.001 b0.001
Linear p value b0.001 b0.001 b0.001 b0.001 b0.001
Nonlinear p value b0.001 b0.001 b0.001 0.83 0.16
Abbreviations: ES, effect size; QALY, quality-adjusted life-years; HRQoL, health-related qua
⁎ Select items from Heinrich's and Lehman's HRQoL scales measuring aspects of function
† Score ≥4 (moderate) on at least three or ≥5 (moderately severe) on at least two nega
‡ Score ≥4 (moderate) on at least 3, or ≥5 (moderately severe) on at least 2 positive sunor prominent negative symptoms (n = 575; 40.0%); (b) only promi-
nent negative symptoms (n = 274; 18.9%); (c) only prominent positive
symptoms (n = 295; 20.4%); or (d) both prominent positive and neg-
ative symptoms (n = 303; 20.9%). Prominent negative and positive
symptoms were deﬁned according to criteria as having a score ≥4
(moderate) on at least three, or ≥5 (moderately severe) on at least
two subscale items in the respective subscale. For example, an individ-
ual with a score ≥4 on at least three PANSS positive items but not on
negative items was categorized as having prominent positive symp-
toms. Conversely, a score ≥4 on at least three PANSS negative items
resulted in a categorization of having prominent negative symptoms.
If an individual had scores≥4 on items for both positive and negative
symptom items, then the individual was categorized as having both
prominent positive and prominent negative symptoms. If an individu-
al did not meet criteria for any of these groups, the individual was cat-
egorized as belonging to the None group (having neither prominent
negative nor prominent positive symptoms). Groups were mutually
exclusive.
Utility scores were derived from the SF-12 scores (Brazier and
Roberts, 2004), using software provided by Brazier that converts
SF-12 to SF-6D scores. Similarly, health burden of illness utility scores
were computed, based on PANSS scores, using a method developed
by Lenert et al. (Lenert et al., 2004; Lenert et al., 2005)), in which
PANSS scores are divided into eight groups ranging from mild (pa-
tients with a mean score on negative factor [G7, G16, N1, N2, N3,
N4, N6] b2.1, a positive factor [G9, P1, P3, P5, P6] mean of b2.7, and
a cognitive factor [G5, G10, G11, G12, G13, G15, P2, N5] mean of
b2.9) to extremely severe (patients with a negative factor of N3.4
and a positive factor of N3.9). Lenert et al. (2004) used a panel of
620 persons to rate video presentations reﬂecting these symptom
levels. These ratings were subsequently used to assign health state
classiﬁcation utility weights ranging from 0.88 for mild to 0.42 for ex-
tremely severe symptoms.
Mean differences between the various symptomprominence groups
(positive only, negative only, both positive and negative, or neither
positive nor negative) on the PANSS, SF-12, SF-6D, caregiver lost work-
days in or out of the home (Family/Caregiver Baseline Interview), and
Index of Functioning (consisting of items from Lehman's and Heinrich's
HRQoL scales) were examined. We examined the data using analysis ofy, Lost Workdays of Caregiver, and Functioning Items from the HRQoL Scale, Mean and
ity and
vs.
oup
Health Utility Weights
of PANSS Symptom
Prominence Groups
Caregiver Lost Workdays
Outside or Within Household
in Past Month Due to Family
Member Illness
Functioning
Items of HRQoL
Scale⁎
36)
0.732
(0.725; 0.739)
1.73 (1.21; 2.24)
n = 244
0.99
(0.72; 1.28)
11)
her
.21
0.565
(0.555; 0.576)
1.81 (1.07; 2.55)
n = 119
−0.75
(−1.13; −0.37)
98)
her
.30
0.679
(0.669; 0.688)
2.17 (1.40; 2.94)
n = 108
0.34
(−0.05; 0.74)
99)
her
.31
0.564
(0.554; 0.574)
3.28 (2.55; 3.90)
n = 143
−1.29
(−1.67; −0.91)
b0.001 b0.001 b0.001
b0.001 b0.004 b0.001
b0.01 0.16 0.78
lity of life; PANSS, Positive and Negative Symptom Scale; SF, Short Form.
ing that did not overlap with negative symptoms as per Rabinowitz et al. (2012).
tive subscale items.
bscale items.
Table 2
SF-12 by Prominence of PANSS Negative and Positive Symptoms, Mean and 95% Conﬁdence Interval.
None
(n = 575)
Negative
(n = 274)
Positive
(n = 295)
Negative
and Positive
(n = 303)
p Overall
p Linear
p Nonlinear
Mental (high is better) 43.26
(42.32; 44.20)
41.00
(39.63; 42.37)
39.43
(38.12; 40.74)
37.86
(36.55; 39.17)
b0.0001
b0.0001
= 0.83
Physical (high is better) 48.43
(47.60; 49.26)
47.53
(46.31; 48.74)
48.02
(46.86; 49.18)
48.63
(47.47; 49.78)
= 0.56
= 0.88
= 0.36
Items with statistically signiﬁcant differences⁎
During the past 4 weeks, how much of the time have you had any of the following problems with your work or other regular daily activities as a result of any emotional
problems (such as feeling depressed or anxious)?
1. Accomplished less than you would like
(1-Yes; 2-No)
0.48
(0.43; 0.52)
0.56
(0.50; 0.62)
0.62
(0.56; 0.67)
0.60
(0.54; 0.65)
b0.001
b0.001
= 0.16
2. Didn't do work or other activities as carefully as usual (1-Yes; 2-No) 0.40
(0.36; 0.45)
0.50
(0.44; 0.56)
0.53
(0.47; 0.58)
0.54
(0.48; 0.59)
b0.001
b0.001
= 0.30
3. During the past 4 weeks how much did pain interfere with your normal work
(including both work outside the home and housework)? (1-Not at all; 5-Extremely)
1.76
(1.66; 1.86)
1.90
(1.76; 2.04)
2.05
(1.92; 2.19)
1.84
(1.71; 1.98)
= 0.006
= 0.049
= 0.013
4. Have you felt calm and peaceful? (1-All of the time; 6-None of the time) 3.25
(3.13; 3.36)
3.26
(3.09; 3.42)
3.50
(3.34; 3.66)
3.53
(3.37; 3.69)
= 0.005
= 0.001
= 0.44
5. Did you have a lot of energy? (1-All of the time; 6-None of the time) 3.56
(3.44; 3.67)
3.79
(3.63; 3.96)
3.57
(3.41; 3.73)
3.95
(3.79; 4.11)
b0.001
= 0.001
= 0.009
6. Have you felt downhearted and blue?
(1-All of the time; 6-None of the time)
4.44
(4.33; 4.55)
4.26
(4.10; 4.42)
4.13
(3.98; 4.29)
3.88
(3.72; 4.03)
b0.001
b0.001
= 0.77
12. During the past 4 weeks how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting with friends, relatives, etc.)?
(1-All of the time; 5-None of the time)
3.64
(3.54; 3.75)
3.43
(3.28; 3.59)
3.21
(3.07; 3.36)
3.19
(3.04; 3.33)
b0.001
b0.001
= 0.37
⁎ Items without statistically signiﬁcant differences (1 to 5): (1) general health, (2–3) limitations in doing moderate activities and more strenuous activities (4–5), physical health
limiting accomplishment or work.
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for the presence/absence of a linear trend to assesswhether each subse-
quent categorywas associatedwith greater impact on functional health.
3. Results
Table 1 presents the PANSS, SF-12 mental health score, SF-6D util-
ity, lost workdays of caregiver, and functioning items from the HRQoL
scale. The PANSS total score was 62 for the None (neither prominent
positive nor negative symptoms) group, 95 for the both (prominent
positive and negative symptoms) group, and 78 and 80 for the prom-
inent positive and prominent negative symptom groups, respectively.
In addition, the positive symptom group had a higher positive score
and the negative symptom group, a higher negative score. There
were no statistically signiﬁcant differences (all p's N .11) between
the groups on age (overall mean 40.54 SD 11.10), sex (25.8% female,
74.2% male), race (61.2% white) and marital status (59.5% never mar-
ried). Patients with negative symptom prominence were least likely
to have completed high school (66.1%), followed by those with prom-
inence on both positive and negative (72.3%), those with no promi-
nent symptoms (76.5%), and those with prominent positive
symptoms (80.3%) (Chi-square = 17.65, df = 3, p = .001).
On the SF-12 and the SF-6D utility, there was a signiﬁcant linear
decline for each subsequent group such that the pattern of decline
was signiﬁcant, with the combination of prominent positive and
negative symptoms further increasing the decline. Individuals with
neither prominent positive nor prominent negative symptoms had
the highest quality-adjusted life-years, followed by individuals
with only prominent negative symptoms, only prominent positive
symptoms, and both prominent positive and negative symptoms
(respectively, 0.725 [95% CI, 0.714 to 0.736]; 0.697 [95% CI, 0.681 to
0.713]; 0.685 [95% CI, 0.670 to 0.701] and 0.683 [95% CI, 0.668
to 0.698]). The effect sizes versus the comparator group, the groupwith neither prominent positive nor prominent symptoms on utility
were 0.21, 0.30, and 0.31, respectively.
The number of workdays missed by caregivers in the month prior
to CATIE had the expected linear decline across symptom groups. The
functioning scale (from HRQoL scales) showed signiﬁcantly greater
(p b 0.001) functional impairment for the prominent negative symp-
tom group than the prominent positive symptom group (data not
presented in table), and a similar additive effect (i.e., most impair-
ment), as with other measures in individuals with both prominent
positive and negative symptoms (Table 1). Similar to the mental
health score, there were also signiﬁcant differences (p b 0.006)
among all seven mental health items measuring work and daily activ-
ities, feeling calm, depression, energy, and social activities, which
were signiﬁcantly linear for ﬁve items (Table 2). There was no signiﬁ-
cant difference in physical health or among any physical health items
(Table 2).
4. Discussion
Prominent positive andnegative symptomswere common in a cohort,
primarily of outpatients, with schizophrenia, receiving antipsychotics.
Using criteria for prominent symptoms, we showed that 19% of individ-
uals were classiﬁed as having prominent negative symptoms, 20% as hav-
ing prominent positive symptoms, and 21% as having both prominent
positive and prominent negative symptoms. The coexistence of promi-
nent positive and negative symptoms was independently associated
with a signiﬁcant decline in functional mental health, health utility and
well-being, health related quality of life, and caregiver burden. Negative
symptoms were more associated with impairment, as measured by the
scale of functioning, than positive symptoms.
These results suggest that outpatients with prominent positive,
prominent negative, or both prominent positive and negative symp-
toms of schizophrenia may experience an improvement in HRQoL
342 J. Rabinowitz et al. / Schizophrenia Research 150 (2013) 339–342by treating either domain of psychopathology. It has been previously
recognized (Alonso et al., 2009) that treating positive symptoms may re-
sult in improved HRQoL; however, results of the current analysis suggest
a distinct improvement in HRQoL as a consequence of treating prominent
negative symptoms as well. These ﬁndings are consistent with studies
that have demonstrated that negative symptoms, particularly apathy
and avolition, are related to poor community outcomes such as poor so-
cial functioning, poor work functioning, and remission (Kirkpatrick and
Buchanan, 1990; Fenton and McGlashan, 1991).
In this study of a broadly inclusive randomized controlled trial, we
found that the presence of positive and negative symptomswas associ-
ated with increased burden, as represented by the results of the group
with both prominent positive and prominent negative symptoms.
Althoughnegative symptomsare a predictor of poor patient functioning
and can affect a patient's ability to live independently, perform activities
of daily living, be socially active, and maintain personal relationships
(Novick et al., 2009; Harvey et al., 2012; Rabinowitz et al., 2012),
there have been no studies speciﬁcally designed to assess health eco-
nomic aspects related to negative symptoms.
The limitations of the current study include concerns regarding
the representativeness of the CATIE sample. Although individuals
were managed in a variety of community treatment settings, those
agreeing to participate in the trial were likely to be dissatisﬁed
with their current treatment. Individuals who declined participation
may have had lower levels of positive and negative symptoms. Also
the study was conducted in a single country. Our use of caregiver
days lost from work is only an indirect indicator of family burden.
In addition, the PANSS has relatively few items for scoring negative
symptoms, particularly apathy and avolition.
In conclusion, both prominent positive and prominent negative symp-
toms of schizophrenia are independently associated with signiﬁcant de-
cline in functionality, HRQoL, and caregiver lost workdays. An increased
burden is observed in patients with highest symptomatology.
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